Osteoarthritis Articles & Analysis
46 news found
Cebranopadol has been studied extensively for its safety and efficacy in approximately 2,000 individuals through multiple clinical trials across Europe and the United States, including in subjects with moderate to severe acute postoperative pain following bunionectomy, chronic pain due to painful diabetic polyneuropathy, chronic pain due to osteoarthritis of the knee, chronic low ...
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of ...
ByEmovi
Some of the most common athletic injuries that regenerative therapy injections can cure include: ACL tears, tennis elbow, rotator cuff injuries, osteoarthritis, and damaged achilles tendons. Two of the main types of regenerative therapy include prolotherapy and platelet rich plasma. ...
Further, Harris Poll ran step-wise regression to isolate the individual impacts of nearly a dozen common chronic diseases (e.g., obesity, diabetes, osteoarthritis, rheumatoid arthritis, and stroke), and CLBP was the leading cause of reduced mobility (see chart above; See also Full Report here). ...
Both glucosamine and chondroitin are reduced in osteoarthritis. Clinically, active supplementation of glucosamine and chondroitin can relieve the symptoms of arthritis. Therefore, it is widely used to treat osteoarthritis and arthritis pain.D-glucosamine is a monosaccharide containing an amine group instead of a hydroxyl group. ...
The patient, a 52 year old male, had isolated osteoarthritis in his left knee. The patient is expected to have many years of pain-relief and return to active lifestyle. ...
Our work on advanced arthritis has been accepted by the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and two other papers have recently been published in Plos One and the European Journal of Dermatology. ...
“Knee pain affects one person out of five and includes sports injuries and structural diseases such as knee osteoarthritis (‘OA’), which is among the leading causes of disability in the United States, costing billions of dollars each year in lost work hours, treatments, doctor visits, and leaves people sidelined from day-to-day activities,” said Michelle ...
ByEmovi
Prior to enrollment, each participating subject was screened and verified to have met all eligibility criteria, including: having early to moderate symptomatic, single-level DDD from L3-S1, no previous lumbar spine surgery, no radiculopathy (pinched nerve) or leg pain, and no comorbidities, such as tumors, fibromyalgia, systemic disease, osteoarthritis or chronic opioid usage. ...
Building on the insights obtained from years of research studying regenerative cells, InGeneron is currently conducting three actively enrolling FDA-approved clinical trials. to evaluate its cell therapy platform for the treatment of musculoskeletal indications such as partial-thickness rotator cuff tear, wrist osteoarthritis, and facet joint syndrome. About the Transpose® ...
In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to pain and instabilities of an orthopedic cause such as those associated with knee osteoarthritis, anterior knee pain, and ligament injuries. By providing a functional and objective knee assessment with a higher ...
ByEmovi
” Building on the insights obtained from years of research studying vaPS cells, InGeneron is currently conducting three actively enrolling FDA-approved clinical trials to evaluate its cell therapy platform for the treatment of musculoskeletal indications such as partial thickness rotator cuff tear, wrist osteoarthritis, and facet joint syndrome. About the Transpose® ...
In April 2019 Active Implants was selected as a partner in the MEFISTO Project: (Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy). The goal of the project is to develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. ...
Some of the first applications to be commercialized include scanning carotid arteries to assess the risk for stroke, the thyroid and breast to determine whether detected nodules may be malignant, and even assessing and monitoring osteoarthritis and rheumatoid arthritis in the knee, wrist or other parts of the body. ...
KiOmed Pharma offers a unique pipeline of products for tackling invalidating osteoarthritis, skin aging and dry eye ...
Results of the study include: 84% of patients treated with the NUsurface Implant experienced a 10-point improvement from baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain, which is considered the minimum clinically relevant improvement in pain and function. 89% of patients who received the NUsurface Implant completed 24 months of follow-up. ...
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, ...
” The KneeKG is the first clinically validated tool that meets the global needs of clinicians for objective and quantifiable biomechanical markers linked to pain and instabilities of an orthopedic cause, such as those associated with knee osteoarthritis, anterior knee pain, and ligament injuries. It assesses and documents the knee in motion and highlights, with high ...
ByEmovi
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with advanced stage ...
Tanezumab 2.5 mg administered subcutaneously (SC) every eight weeks is being evaluated for the treatment of moderate-to-severe osteoarthritis (OA) pain in adult patients for whom use of other analgesics is ineffective or not appropriate. ...